Current applications of therapeutic phlebotomy

Blood Transfusion

Volumn 12, Issue SUPPL.1, 2014, Pages

  Assi, Tarek Bou ^a   Baz, Elizabeth ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Bloodletting; Haemochromatosis; Polycythaemia vera; Porphyria cutanea tarda.; Therapeutic phlebotomy

Indexed keywords

ANEMIA, SICKLE CELL; BIOPSY; COMPLEMENTARY THERAPIES; DIAGNOSIS, DIFFERENTIAL; ERYTHROPOIETIN; HEMOCHROMATOSIS; HEPATITIS C, CHRONIC; HUMANS; IRON; KIDNEY TRANSPLANTATION; LIVER; METABOLIC SYNDROME X; PHLEBOTOMY; POLYCYTHEMIA; POLYCYTHEMIA VERA; PORPHYRIA CUTANEA TARDA; POSTOPERATIVE COMPLICATIONS;

EID: 84893955379     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0299-12     Document Type: Review

References (73)

1. Parapia LA. History of bloodletting by phlebotomy. Br J Haematol 2008; 143: 490-5.
2. Schneeberg NG. A twenty-first century perspective on the ancient art of bloodletting. Trans Stud Coll Physicians Phila 2002; 24: 157-85.
3. Estes JW. George Washington and the doctors: treating America's first superhero. Med Herit 1985; 1: 44-57.
4. Cook LS. Therapeutic phlebotomy: a review of diagnoses and treatment considerations. J Infus Nurs 2010; 33: 81-8.
5. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975; 12: 339.
6. Pearson TC. Apparent polycythaemia. Blood Rev 1991; 5: 205-13.
7. Messinezy M, Pearson TC. Apparent polycythaemia: diagnosis, pathogenesis and management. Eur J Haematol 1993; 51: 125-31.
8. Humphrey PR, Michael J, Pearson TC. Red cell mass, plasma volume and blood volume before and after venesection in relative polycythaemia. Br J Haematol 1980; 46: 435-8.
9. Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med 1997; 102: 14-20.
10. van Genderen PJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 1997; 23: 357-63.
11. Thiele J, Kvasnicka HM, Orazi A, et al. Myeloproliferative neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al. (eds.): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon; 2008. p.40-3.
12. Fallah M, Kharazmi E, Sundquist J, Hemminki K. Higher risk of primary cancers after polycythaemia vera and vice versa. Br J Haematol 2011; 153: 283-5.
13. Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132-43.
14. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (eds), WB Saunders, Philadelphia; 1995. p.166.
15. [No authors listed]. Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP). Br J Haematol 1997; 97: 453-6.
16. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34: 17-23.
17. Newman BH, Pichette S, Pichette D, Dzaka E. Adverse effects in blood donors after whole-blood donation: a study of 1000 blood donors interviewed 3 weeks after whole-blood donation. Transfusion 2003; 43: 598-603.
18. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978; 2: 1219-22.
19. Thomas DJ, du Boulay GH, Marshall J, et al. Cerebral bloodflow in polycythaemia. Lancet 1977; 2: 161-3.
20. Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007; 136: 249-59.
21. Marchioli R, Finazzi G, Specchia G, et al. The CYTO-PV: a large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis 2011; 2011: 794240.
22. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368: 22-33.
23. Bornstein R, Menon D, York E, et al. Effects of venesection on cerebral function in chronic lung disease. Can J Neurol Sci 1980; 7: 293-6.
24. Shah DM, Powers SR Jr, Bernard HR, et al. Increased oxygen uptake following phlebotomy and simultaneous fluid replacement in polycythemic patients. Surgery 1980; 88: 686-92.
25. Chetty KG, Light RW, Stansbury DW, Milne N. Exercise performance of polycythemic chronic obstructive pulmonary disease patients. Effect of phlebotomies. Chest 1990; 98: 1073-7.
26. Piccirillo G, Fimognari FL, Valdivia JL, Marigliano V. Effects of phlebotomy on a patient with secondary polycythemia and angina pectoris. Int J Cardiol 1994; 44: 175-7.
27. Tripathy S, Panda SS, Rath B. Phlebotomy for rapid weaning and extubation in COPD patient with secondary polycythemia and respiratory failure. Lung India 2010; 27: 24-6.
28. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/ erythrocytosis. Br J Haematol. 2005; 130: 174-95.
29. Barenbrock M, Spieker C, Rahn KH, Zidek W. Therapeutic efficiency of phlebotomy in posttransplant hypertension associated with erythrocytosis. Clin Nephrol 1993; 40: 241-3.
30. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. Kidney Int 2003; 63: 1187-94.
31. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118: e714-833.
32. Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis, and treatment. Am J Hematol 2006; 81: 202-9.
33. Roetto A, Totaro A, Piperno A, et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001; 97: 2555-60.
34. Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108: 619-23.
35. Gordeuk VR, Caleffi A, Corradini E, et al. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003; 31: 299-304.
36. Visapää I, Fellman V, Vesa J, et al. GRACILE syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation in BCS1L. Am J Hum Genet 2002; 71: 863-76.
37. Whitington PF. Neonatal hemochromatosis: a congenital alloimmune hepatitis. Semin Liver Dis 2007; 27: 243-50.
38. Trousseau A. Glycosurie, diabète sucré. In: Clinique Médicale de l'Hôtel-Dieu de Paris. 2nd ed. Vol. 2; 1865. p. 663-98.
39. von Recklinghausen FD. Ueber Haemachromatose. Berl Klin Wochenschr 1889; 26: 925.
40. Sheldon JH. Haemochromatosis. London, UK: Oxford University Press; 1935. p. 164-340.
41. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
42. Sanchez AM, Schreiber GB, Bethel J, et al. Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis. JAMA 2001; 286: 1475-81.
43. Guidance for Industry: Variances for Blood Collection from Individuals with Hereditary Hemochromatosis. Food and Drug Administration. Available at: http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm076719.htm, Accessed on 24/10/2012.
44. Pietrangelo A. Molecular insights into the pathogenesis of hereditary haemochromatosis. Gut 2006; 55: 564-8.
45. Ahmad KA, Ahmann JR, Migas MC, et al. Decreased liver hepcidin expression in the Hfe knockout mouse. Blood Cells Mol Dis 2002; 29: 361-6.
46. Siah CW, Ombiga J, Adams LA, et al. Normal iron metabolism and the pathophysiology of iron overload disorders. Clinic Biochem Rev 2006; 27: 5-16.
47. McLaren CE, McLachlan GJ, Halliday JW, et al. Distribution of transferrin saturation in an Australian population: Relevance to early diagnosis of hemochromatosis. Gastroenterology 1998; 114: 543-9.
48. McDonnell SM, Preston BL, Jewell SA, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999; 106: 619-24.
49. Falize L, Guillygomarc'h A, Perrin M, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44: 472-7.
50. Andersen RV, Tybjaerg-Hansen A, Appleyard M, et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103: 2914-9.
51. Adams PC, Barton JC. How I treat hemochromatosis. Blood 2010; 116: 317-25.
52. Bolan CD, Conry-Cantilena C, Mason G, et al. MCV as a guide to phlebotomy therapy for hemochromatosis. Transfusion 2001; 41: 819-27.
53. Rombout-Sestrienkova E, Nieman FH, Essers BA, et al. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion 2012; 52: 470-7.
54. Elder GH. Porphyria cutanea tarda. Semin Liver Dis 1998; 18: 67-75.
55. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003; 39: 620-7.
56. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007; 46: 1071-80.
57. Deacon AC, Elder GH. ACP Best Practice No 165: front line tests for the investigation of suspected porphyria. J Clin Pathol 2001; 54: 500-7.
58. Aarsand AK, Boman H, Sandberg S. Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clin Chem 2009; 55: 795-803.
59. Ramsay CA, Magnus IA, Turnbull A, Baker H. The treatment of porphyria cutanea tarda by venesection. Q J Med 1974; 43: 1-24.
60. Rocchi E, Gibertini P, Cassanelli M, et al. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. J Lab Clin Med 1986; 107: 36-42.
61. Cainelli T, Di Padova C, Marchesi L, et al. Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda. Br J Dermatol 1983; 108: 593-600.
62. Rocchi E, Gibertini P, Cassanelli M, et al. Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion. Br J Dermatol 1986; 114: 621-9.
63. Epstein JH, Redeker AG. Porphyria cutanea tarda symptomatica (PCT-S). A study of the effect of phlebotomy therapy. Arch Dermatol 1965; 92: 286-90.
64. Di Padova C, Marchesi L, Cainelli T, et al. Effects of phlebotomy on urinary porphyrin pattern and liver histology in patients with porphyria cutanea tarda. Am J Med Sci 1983; 285: 2-12.
65. Chlumský J, Malina L, Chlumská A. The effect of venesection therapy on liver tissue in porphyria cutanea tarda. Acta Hepatogastroenterol (Stuttg) 1973; 20: 124-30.
66. Dwyer BE, Zacharski LR, Balestra DJ, et al. Getting the iron out: phlebotomy for Alzheimer's disease? Med Hypotheses 2009; 72: 504-9.
67. Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. NNCI. J Natl Cancer Inst. 2008; 100: 996-1002.
68. Houschyar KS, Lüdtke R, Dobos GJ, et al. Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med 2012; 10: 54.
69. Desai TK, Jamil LH, Balasubramaniam M, et al. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 2008; 53: 815-22.
70. Sartoria M, Andornoa S, Rossinic A, et al. A case-control histological study on the effects of phlebotomy in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2011; 23: 1178-84.
71. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-30.
72. Bouchaïr N, Manigne P, Kanfer A, et al. Prevention of sickle cell crises with multiple phlebotomies. Arch Pediatric 2000; 7: 249-55.
73. Rombos Y, Tzanetea R, Kalotychou V, et al. Amelioration of painful crises in sickle cell disease by venesections. Blood Cells Mol Dis 2002; 28: 283-7.